<DOC>
	<DOCNO>NCT00537732</DOCNO>
	<brief_summary>Patients gastroesophageal reflux disease ( GERD ) either treat 4 week standard dose ( 20mg ) omeprazole , drug first choice , individualize dosing ( 20 60mg/day ) accord fast patient metabolize ( eliminate ) drug . The individual elimination capacity genetically control therefore patient genotyped prior therapy .</brief_summary>
	<brief_title>Omeprazole Reflux Disease - Improvement Clinical Outcome Genotype-adjusted Dosing</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Patients GERD grade A B ( mild moderate severe disease ) diagnose routine endoscopy recruit different clinical ambulant centre gastroenterology ; write informed consent obligatory Range Age : 2070 BMI : 2030 Patients allergic protonpump inhibitor show incompatibility Patients lactase deficiency Patients severe chronic disease Patients participate another study last three month Patients pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>gastro-oesophageal reflux disease</keyword>
</DOC>